New York,United States, April 2026 — Jon F. has started a new position as Associate Vice President of Business Development at Axsome Therapeutics, Inc. His elevation marks a significant step forward in his business development leadership journey at the company, where he has already been contributing to strategic growth initiatives in the biopharmaceutical sector. In this new role, he is expected to further strengthen Axsome’s business development agenda as the company continues to advance novel therapies for central nervous system conditions.
Before this promotion, Jon F. served at Axsome Therapeutics, Inc. as Executive Director, Business Development, where he led business development initiatives for the mid-cap public biopharma company. His work in this role positioned him at the center of Axsome’s strategic efforts as it continued developing and delivering therapies for CNS disorders.
Prior to joining Axsome Therapeutics, Inc., he worked at Sage Therapeutics as Senior Director, Corporate Strategy and Business Development, where he was involved in buy-side and sell-side business development for a novel CNS portfolio. Earlier, he had also held roles at Sage Therapeutics as Director, New Product Planning & Global Commercial Strategy and Associate Director, New Product Planning, where he served as the commercial lead for early-stage neurology programs. These assignments gave him strong exposure to portfolio strategy, commercialization planning, and growth-oriented decision-making in neuroscience and CNS-focused businesses.
He also served at Radius Health, Inc. as Senior Director, Capital, Strategy & Transactions – Neuroscience, where he led search and evaluation for the neuroscience portfolio and handled direct ownership of buy-side and sell-side activities related to the neuroscience business. In this role, he also served as commercial lead for the RAD011 program for Prader-Willi syndrome and rare epilepsy syndromes, which had been acquired from Benuvia Therapeutics. This phase of his career further deepened his experience in transactions, portfolio strategy, and commercial leadership.
Earlier in his professional journey, Jon F. built a strong consulting foundation at Trinity Life Sciences, where he progressed through roles including Engagement Manager, Consultant, and Senior Associate. During this period, he worked in management consulting for life sciences companies, building expertise that would later support his transition into strategic and corporate business development leadership roles within the biopharma industry.
His career path reflects a strong and consistent focus on central nervous system therapies, neuroscience portfolios, strategic transactions, and business development. With experience spanning consulting, product planning, corporate strategy, transactions, and business development leadership, Jon F. brings a well-rounded perspective to his new role at Axsome Therapeutics, Inc.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system conditions that have limited treatment options. Through the development of therapeutic options with novel mechanisms of action, the company is transforming the approach to treating CNS conditions. Axsome is focused on meaningfully improving the lives of patients while providing additional therapeutic options for physicians.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
